Research Comparison
Retatrutide (LY3437943) vs Tirzepatide
A side-by-side research comparison of Retatrutide (LY3437943) and Tirzepatide drawn from Cobalt Peptides' peptide database records.
Retatrutide (LY3437943)
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist with activity at the GLP-1, GIP and glucagon receptors. Its design combines incretin-axis signalling through GLP-1 and GIP with glucagon receptor activity, a combination studied for its effects on energy balance in published metabolic research. Retatrutide is not an approved medicine in the United Kingdom or elsewhere and remains in clinical development by its originator. Supplied strictly as a research compound for laboratory use.
Tirzepatide
Tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Engaging both incretin receptors is what distinguishes it from GLP-1-only compounds, and the published literature describes effects on insulin secretion, glucagon suppression and gastric emptying. Licensed medicines containing tirzepatide exist and are prescribed by clinicians; the material supplied here is a research compound and is not one of them.